Antimicrobial Therapeutics Reviews

Antibiotics That Target the Ribosome, Volume 1241
Herausgeber: Bush, Karen

• Broschiertes Buch

Produktbeschreibung

"This second installment of Antimicrobial Therapeutics Reviews presents scholarly reviews on several key areas in the field of antimicrobial therapeutics, including several papers on issues relating to antibiotics that target the ribosome. Topics covered include plasmid-encoded resistance determinants for agents that bind the ribosome, new compound classes targeting the ribosome, sequence-specific action of antibiotics binding the ribosome, smFRET approaches to determine MOA of antibiotics binding to the ribosome, new approaches for treating Staphylococcus biofilm infections, and the history of tetracyclins. The volume also features reviews dealing with drug development, such as pleuromutilin discovery and development challenges and an update on newer oxazolidinones such as torezolid and radezolid, and a review on regulatory hurdles for new antibiotics"--

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Verlag: Wiley
• Seitenzahl: 184
• Erscheinungstermin: 14. Mai 2012
• Englisch
• Abmessung: 249mm x 175mm x 8mm
• Gewicht: 386g
• ISBN-13: 9781573318488
• ISBN-10: 1573318485
• Artikelnr.: 35230626

Autorenporträt

Karen Bush is the editor of Antimicrobial Therapeutics Reviews: Antibiotics that Target the Ribosome, Volume 1241, published by Wiley.

Inhaltsangabe

Introduction to Antimicrobial therapeutics reviews : antibiotics that
target the ribosome
On the specificity of antibiotics targeting the large ribosomal subunit
The history of the tetracyclines
Macrolide antibiotics in the ribosome exit tunnel : species-specific
binding and action
The oxazolidinones : past, present, and future
Are pleuromutilin antibiotics finally fit for human use?
Plasmid-mediated resistance to protein biosynthesis inhibitors in
staphylococci
New approaches for treating staphylococcal biofilm infections
Antibiotics in development targeting protein synthesis
Understanding the regulatory hurdles for antibacterial drug development in
the post-Ketek world
Aureomycin : a product of the continuing search for new antibiotics